ADRB2 Gly16Arg polymorphism, asthma control and lung function decline

European Respiratory Journal

Volumn 38, Issue 5, 2011, Pages 1029-1035

  Rebordosa, C ^a,b   Kogevinas, M ^c,d,e   Guerra, S ^c,d   Castro Giner, F ^c   Jarvis, D ^f   Cazzoletti, L ^g   Pin, I ^h   Siroux, V ⁱ   Wjst, M ^j   Anto J M ^f   De Marco, R ^k   Estivill, X ^l   Corsico, A G ^m   Nielsen, R ⁿ   Janson, C ^o  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITY OF ARIZONA   (United States)

^c CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^d CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^e NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^f NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^g UNIVERSITY OF VERONA   (Italy)

^h GRENOBLE UNIVERSITY HOSPITAL   (France)

ⁱ INSERM   (France)

^j INSTITUTE OF EPIDEMIOLOGY   (Germany)

^k Dept Medicina e Sanità Pubblica   (Italy)

^l CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^m UNIVERSITY OF PAVIA   (Italy)

ⁿ HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^o UPPSALA UNIVERSITY   (Sweden)

more..

Author keywords

2 adrenoreceptor polymorphisms; Asthma control; Bronchial hyperresponsiveness; Corticosteroids; Lung function

Indexed keywords

ARGININE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; GLYCINE;

ADRB2 GENE; ADULT; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; DISEASE CONTROL; DRUG RESPONSE; FEMALE; FORCED EXPIRATORY VOLUME; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; ALLELES; ASTHMA; BRONCHIAL HYPERREACTIVITY; DELAYED-ACTION PREPARATIONS; FEMALE; FORCED EXPIRATORY VOLUME; GENOTYPE; GLUCOCORTICOIDS; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ADRENERGIC, BETA-2; RESPIRATORY FUNCTION TESTS;

EID: 80355148633     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00146310     Document Type: Article

References (32)

1. Castro-Giner F, Kauffmann F, de Cid R, et al. Gene-environment interactions in asthma. Occup Environ Med 2006; 63: 776-786. (Pubitemid 44682645)
2. Hawkins GA, Weiss ST, Bleecker ER. Clinical consequences of ADRb2 polymorphisms. Pharmacogenomics 2008; 9: 349-358.
3. 2- adrenergic receptor gene and desensitization in human airway smooth muscle. Am J Respir Crit Care Med 2000; 162: 2117-2124.
4. 2-adrenergic receptor tolerance in human small airways. J Allergy Clin Immunol 2008; 122: 734-740.
5. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364: 1505-1512. (Pubitemid 39410416)
6. Wechsler ME, Lehman E, Lazarus SC, et al. β-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006; 173: 519-526.
7. Tattersfield AE, Harrison TW. β-Adrenoceptor polymorphisms: focus moves to long-acting β-agonists. Am J Respir Crit Care Med 2006; 173: 473-474.
8. 2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet 2009; 374: 1754-1764.
9. 2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med 2009; 181: 676-687.
10. Janson C, Anto J, Burney P, et al. The European Community Respiratory Health Survey: what are the main results so far? Eur Respir J 2001; 18: 598-611. (Pubitemid 32895647)
11. National Heart Lung and Blood Institute, Global Initiative for Asthma. Global strategy for Asthma Management and Prevention. NHLBI/WHO Workshop Report. National Heart Lung and Blood Institute publication no. 02-3659. Bethesda, National Institutes of Health, 2006.
12. Cazzoletti L, Marcon A, Janson C, et al. Therapy and Health Economics Group of the European Community Respiratory Health Survey. Asthma control in Europe: a real-world evaluation based on an international population-based study. J Allergy Clin Immunol 2007; 120: 1360-1367. (Pubitemid 350225685)
13. Chinn S, Arossa WA, Jarvis DL, et al. Variation in nebulizer aerosol output and weight output from the Mefar dosimeter: implications for multicentre studies. Eur Respir J 1997; 10: 452-456. (Pubitemid 27063867)
14. De Marco R, Marcon A, Jarvis D, et al. ECRHS Therapy Group. Inhaled steroids and lung function decline in asthma. J Allergy Clin Immunol 2007; 119: 611-617.
15. Castro-Giner F, Kogevinas M, Imboden M, et al. Joint effect of obesity and TNFA variability on asthma: two international cohort studies. Eur Respir J 2009; 33: 1003-1009.
16. Clayton DG, Walker NM, Smyth DJ, et al. Population structure, differential bias and genomic control in a large-scale, case-control association study. Nat Genet 2005; 37: 1243-1246. (Pubitemid 41568707)
17. Price AL, Patterson NJ, Plenge RM, et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-909. (Pubitemid 44141658)
18. Castro-Giner F, Künzli N, Jacquemin B, et al. Traffic-related air pollution, oxidative stress genes, and asthma (ECHRS). Environ Health Perspect 2009; 117: 1919-1924.
19. 2-adrenergic receptor polymorphisms with asthma phenotypes. J Allergy Clin Immunol 2005; 115: 963-972.
20. McGraw DW, Almoosa KF, Paul RJ, et al. Antithetic regulation by β-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway β-agonist paradox. J Clin Invest 2003; 112: 619-626. (Pubitemid 38056346)
21. 2-adrenoreceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Br J Pharmacol 2008; 153: 1090-1104.
22. Martinez FD. Safety of long-acting β-agonists - an urgent need to clear the air. N Engl J Med 2005; 353: 2637-2639. (Pubitemid 41817711)
23. Mak JC, Hisada T, Salmon M, et al. Glucocorticoids reverse IL-1β-induced impairment of β-adrenoreceptor-mediated relaxation and up-regulation of G-protein-coupled receptor kinases. Br J Pharmacol 2002; 135: 987-996. (Pubitemid 34214458)
24. Chong LK, Drury DE, Dummer JF, et al. Protection by dexamethasone of the functional desensitization to β2-adrenoreceptor-mediated responses in human lung mast cells. Br J Pharmacol 1997; 121: 717-722. (Pubitemid 27260775)
25. Mak JC, Nishikawa M, Barnes PJ. Glucocorticoids increase β2- adrenergic receptor transcription in human lung. Am J Physiol 1995; 268: L41-L46.
26. sα protein expression in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2000; 278: L1101-L1106.
27. Tan KS, Grove A, McLean A, et al. Systemic corticosteriod rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am J Respir Crit Care Med 1997; 156: 28-35. (Pubitemid 27293163)
28. 2-adrenoreceptor down-regulation after regular inhaled formoterol. Chest 1999; 115: 623-628.
29. Kalra S, Swystun VA, Bhagat R, et al. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest 1996; 109: 953-956. (Pubitemid 26113636)
30. 2-agonists and bronchial hyperresponsiveness. Clin Rev Allergy Immunol 2006; 31: 143-162.
31. 2- adrenoceptor haplotypes on bronchial hyper-responsiveness in patients with asthma. Allergy 2006; 61: 254-259.
32. Kelly MM, O'Connor TM, Leigh R, et al. Effects of budesonide and formoterol on allergen-induced airway responses, inflammation, and airway remodeling in asthma. J Allergy Clin Immunol 2010; 125: 349-356.